title: Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis.
authors.affiliation: a University Hospital of Leipzig , Department of Hematology and Oncology , Leipzig , Germany ;
authors.forename: Haifa Kathrin
authors.initials: HK
authors.lastname: Al-Ali
authors.affiliation: b Novartis Pharma AG , Basel , Switzerland ;
authors.forename: Viktoriya
authors.initials: V
authors.lastname: Stalbovskaya
authors.affiliation: b Novartis Pharma AG , Basel , Switzerland ;
authors.forename: Prashanth
authors.initials: P
authors.lastname: Gopalakrishna
authors.affiliation: b Novartis Pharma AG , Basel , Switzerland ;
authors.forename: Julian
authors.initials: J
authors.lastname: Perez-Ronco
authors.affiliation: c St. Paul's Hospital, University of British Columbia , Vancouver , Canada.
authors.forename: Lynda
authors.initials: L
authors.lastname: Foltz
mesh_terms: D000740:Anemia / Q000175:diagnosis* / Q000209:etiology / Q000473:pathology; D017326:Clinical Trials, Phase III as Topic / Q000706:statistics & numerical data; D005260:Female; D006454:Hemoglobins / Q000032:analysis / Q000187:drug effects*; D006801:Humans; D008297:Male; D009570:Nitriles; D009929:Organ Size / Q000187:drug effects; D055728:Primary Myelofibrosis / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy* / Q000401:mortality; D011379:Prognosis; D011720:Pyrazoles / Q000627:therapeutic use*; D011743:Pyrimidines; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D013154:Spleen / Q000187:drug effects / Q000473:pathology; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D006454:Hemoglobins; D009570:Nitriles; D011720:Pyrazoles; D011743:Pyrimidines; C540383:ruxolitinib